Xenpozyme

Xenpozyme (olipudase alfa) is an enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD). This overview covers its therapeutic role and general handling notes for informed use.

Olipudase alfa is used to treat acid sphingomyelinase deficiency (ASMD), a rare genetic disorder affecting lipid metabolism. It replaces the missing enzyme to help manage symptoms related to lipid buildup in tissues. Patients and caregivers often ask, 'what is olipudase alfa used for' to understand its role in ASMD management.

Olipudase alfa works by breaking down sphingomyelin, a lipid that accumulates in cells due to ASMD. This process may help reduce symptoms such as enlarged liver or spleen and improve overall metabolic function. Common effects include improved organ function over time with regular administration.

Olipudase alfa is administered under medical supervision due to the risk of serious reactions. Patients should report any signs of infusion-related reactions, such as fever or difficulty breathing, immediately. Regular monitoring of liver and lung function is recommended during treatment.

Limited data exists on drug interactions with olipudase alfa. However, caution is advised when combining it with other medications that affect liver function or immune response. Patients should inform their healthcare provider about all medications, including over-the-counter and supplements.